Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepetaprost vs Timolol in Glaucoma or Ocular Hypertension
NCT04742283Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sepetaprost in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Dec 2020; status: completed.
02
Drugs
sepetaprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04742283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742283.